1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Evolutionary Genomics, Inc.

Evolutionary Genomics, Inc.

FNAM
Evolutionary Genomics, Inc.US flagOther OTC
0.00
USD
- -
- -
1,331.00Market Cap
Evolutionary Genomics, Inc.
FNAM
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
0.08
0.05
0.04
0.01
0.02
0.02
- -
- -
- -
- -
Revenue per Share
-0.14
-0.18
-0.13
-0.13
-0.15
-0.31
-0.06
-0.23
-0.13
-0.23
-0.18
-0.34
-0.52
- -
-0.35
Basic EPS, GAAP
-0.09
-0.2
-0.21
-0.11
-0.1
-0.19
-0.12
-0.21
-0.2
-0.13
-0.11
-0.39
-0.27
- -
-0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.38
-9.6
-9.2
-9.2
-10.02
-2.1
-1.99
-1.86
-1.95
-2.14
-2.27
-2.56
-3.04
- -
-3.1
Book Value per Share
-0.07
-0.24
-0.37
-0.48
-0.6
-0.34
0.07
-0.92
-0.52
-0.73
-0.9
-1.14
-1.46
- -
-1.42
Tangible Book Value per Share
- -
- -
- -
- -
- -
5
5
6
6
6
6
6
6
- -
6
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-284.58
-274.93
-475.43
-3,984.79
-728.83
-631.55
-23,038.36
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Depreciation Expense
- -
- -
- -
- -
- -
-1
- -
-1
-1
-1
-1
-2
-3
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-401.97
-108.78
-519.91
-1,650.71
-956.87
-646.48
-13,695.06
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
1
- -
2
1
- -
- -
- -
- -
1
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
4
4
4
LT Debt
- -
- -
- -
- -
- -
- -
3
2
1
- -
- -
-2
-4
-6
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
ST Debt
- -
- -
- -
LT Borrowings
4
4
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
2
2
2
Shares Outstanding
7
7
7
Market Capitalization
4
4
4

Working Capital

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-150.11%
72.25%
27.08%
Free Cash Flow
654.77%
24.72%
-59.51%
Net Income, GAAP
757.09%
44.82%
-30.74%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
9.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.05
-0.06
0.08
- -
-0.34
2021
-0.1
-0.11
-0.19
- -
-0.52
2022
-0.1
-0.09
-0.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Psyence Biomedical Ltd. Warrant (PBMWW)
GeNeuro S.A. (GNRRF)
Xenon Pharmaceuticals Inc. (XENE)
Biophytis S.A. (ALBPS.PA)
Aptevo Therapeutics Inc. (APVO)
Mustang Bio, Inc. (MBIO)
Business
Evolutionary Genomics, Inc. (FNAM) is a genomics research and development company that utilizes its patented Adapted Traits Platform to perform molecular evolution analysis for identifying and validating positively selected genes enhancing commercially valuable traits in crops such as yield, sugar content, biomass, drought tolerance, salt tolerance, and pest/disease resistance. The company offers genes including FusR1 for Fusarium TR4 (Panama disease) resistance in bananas, patented in the United States under number 11913009 issued February 27, 2024 and in various other jurisdictions; EG261 and its orthologs/paralogs for pathogen resistance in soybeans, covered by U.S. patents 8710300, 9834783, 9605274, and 10577625; a gene increasing tomato sweetness by 25% alongside pest resistance genes; and candidate genes for cotton pest resistance and improved fiber length, with applications in rice, corn, wheat, cowpeas, beans, tomatoes, cassava, and other crops. It licenses these genes to seed companies for lump sum payments, milestones, and royalties, targeting the agricultural biotechnology sector serving farmers and agribusinesses globally, including regions threatened by crop diseases like South and Central America. Founded in 1990 by Walter Messier and Virginia Orndorff, Evolutionary Genomics, Inc. is headquartered in Castle Rock, Colorado. Recent developments include the 2024 U.S. patent issuance for the FusR1 banana resistance gene amid ongoing global patent applications in the European Union and elsewhere; prior equity funding of approximately $1 million in March 2022; and continued advancement of soybean, tomato, and cotton gene projects without reported acquisitions, partnerships, or reorganizations in the last two years.